PMID- 14996481
OWN - NLM
STAT- MEDLINE
DCOM- 20040826
LR  - 20151119
IS  - 0167-5273 (Print)
IS  - 0167-5273 (Linking)
VI  - 94
IP  - 1
DP  - 2004 Mar
TI  - Elevated plasma human urotensin-II-like immunoreactivity in ischemic 
      cardiomyopathy.
PG  - 93-7
AB  - BACKGROUND: The recently discovered, vasoactive, cyclic undecapeptide human 
      urotensin-II (hU-II), and its G-protein coupled receptor (GPR14) are both 
      expressed in the human cardiovascular system. Little is known about the 
      pathophysiological relevance of hU-II. We hypothesised that circulating hU-II is 
      elevated in patients with coronary artery disease (CAD) corresponding to the 
      degree of cardiac dysfunction. METHODS: 38 patients were diagnosed with coronary 
      artery disease by left heart catheterization, and their functional status was 
      classified according to the New York Heart Association (NYHA). hU-II-like 
      immunoreactivity (hU-II-LI) was measured using a novel specific and sensitive 
      enzyme-linked immunoassay. Calculations were performed with log-transformed 
      hU-II-LI values. RESULTS: hU-II-LI correlated positively with left ventricular 
      end diastolic pressure (LVEDP) (r=0.32, P=0.05) and tended to correlate inversely 
      with left ventricular ejection fraction (LV-EF) (r=-0.31, P=0.061). There was a 
      positive correlation between hU-II-LI and NYHA class (r=0.53, P=0.001). 
      Circulating hU-II-LI was significantly higher in patients with NYHA class III 
      (4822+/-723 pg/ml, N=13) than in patients with class I (1884+/-642 pg/ml, N=9, 
      P=0.007) or class II (2294+/-426 pg/ml, N=15, P=0.046). There was no difference 
      between classes I and II (P=0.83). Furthermore, hU-II-LI correlated significantly 
      with B-type natriuretic peptide, a marker for heart failure (r=0.40, P=0.025). In 
      a linear regression analysis, NYHA class was the only significant independent 
      predictor of hU-II-LI. CONCLUSIONS: The present study demonstrates that plasma 
      hU-II-LI rises significantly in proportion to parameters of cardiac dysfunction 
      and functional impairment in patients with coronary artery disease. These results 
      suggest a pathophysiological role for hU-II in cardiac disease and warrant 
      further investigation.
FAU - Lapp, Harald
AU  - Lapp H
AD  - Herzzentrum Wuppertal, Helios-Klinikum, Wuppertal, Germany. 
      hlapp@wuppertal.helios-kliniken.de
FAU - Boerrigter, Guido
AU  - Boerrigter G
FAU - Costello-Boerrigter, Lisa C
AU  - Costello-Boerrigter LC
FAU - Jaekel, Karsten
AU  - Jaekel K
FAU - Scheffold, Thomas
AU  - Scheffold T
FAU - Krakau, Ingo
AU  - Krakau I
FAU - Schramm, Matthias
AU  - Schramm M
FAU - Guelker, Hartmut
AU  - Guelker H
FAU - Stasch, Johannes-Peter
AU  - Stasch JP
LA  - eng
PT  - Journal Article
PL  - Netherlands
TA  - Int J Cardiol
JT  - International journal of cardiology
JID - 8200291
RN  - 0 (Biomarkers)
RN  - 0 (Urotensins)
RN  - 9047-55-6 (urotensin II)
SB  - IM
MH  - Biomarkers/blood
MH  - Cardiomyopathy, Dilated/blood/*physiopathology
MH  - Cluster Analysis
MH  - Coronary Artery Disease/physiopathology
MH  - Female
MH  - Heart/physiopathology
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Urotensins/*blood
EDAT- 2004/03/05 05:00
MHDA- 2004/08/27 05:00
CRDT- 2004/03/05 05:00
PHST- 2002/06/23 00:00 [received]
PHST- 2003/04/15 00:00 [revised]
PHST- 2003/05/12 00:00 [accepted]
PHST- 2004/03/05 05:00 [pubmed]
PHST- 2004/08/27 05:00 [medline]
PHST- 2004/03/05 05:00 [entrez]
AID - S0167527303003103 [pii]
AID - 10.1016/j.ijcard.2003.05.008 [doi]
PST - ppublish
SO  - Int J Cardiol. 2004 Mar;94(1):93-7. doi: 10.1016/j.ijcard.2003.05.008.